U.S. patent application number 12/715829 was filed with the patent office on 2010-06-24 for activated dual specificity lymphocytes and their methods of use.
This patent application is currently assigned to The U.S.A. as represented by the Secretary, Dept. of Health and Human Services. Invention is credited to Patrick Hwu, Michael H. Kershaw, Steven A. Rosenberg.
Application Number | 20100158881 12/715829 |
Document ID | / |
Family ID | 25186900 |
Filed Date | 2010-06-24 |
United States Patent
Application |
20100158881 |
Kind Code |
A1 |
Hwu; Patrick ; et
al. |
June 24, 2010 |
ACTIVATED DUAL SPECIFICITY LYMPHOCYTES AND THEIR METHODS OF USE
Abstract
The present invention relates to preventive, therapeutic, and
diagnostic compositions and methods employing lymphocytes having
T-cell receptors and chimeric receptors. In particular, the
invention relates to pre-selected dual-specificity lymphocytes
having endogenous T-cell receptors and chimeric T-cell receptors
that recognize a strong antigen and tumor associated antigens where
the pre-selected population of adoptively transferred lymphocytes
is activated by in vivo immunization, thereby increasing the
effectiveness of adoptive immunotherapy.
Inventors: |
Hwu; Patrick; (Houston,
TX) ; Kershaw; Michael H.; (Victoria, AU) ;
Rosenberg; Steven A.; (Potomac, MD) |
Correspondence
Address: |
LEYDIG, VOIT & MAYER, LTD.
TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH STETSON AVENUE
CHICAGO
IL
60601-6731
US
|
Assignee: |
The U.S.A. as represented by the
Secretary, Dept. of Health and Human Services
Bethesda
MD
|
Family ID: |
25186900 |
Appl. No.: |
12/715829 |
Filed: |
March 2, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09803578 |
Mar 9, 2001 |
|
|
|
12715829 |
|
|
|
|
Current U.S.
Class: |
424/93.21 ;
435/325; 435/372.3 |
Current CPC
Class: |
C12N 5/0636 20130101;
A61K 2039/5156 20130101; A61K 39/0011 20130101; A61K 2039/515
20130101; A61K 35/12 20130101; C12N 2510/00 20130101; C12N 2501/23
20130101 |
Class at
Publication: |
424/93.21 ;
435/325; 435/372.3 |
International
Class: |
A61K 35/26 20060101
A61K035/26; C12N 5/00 20060101 C12N005/00; C12N 5/071 20100101
C12N005/071 |
Claims
1. A composition comprising a T lymphocyte having a chimeric
receptor or T-cell receptor reactive with a tumor antigen and an
endogenous T-cell receptor reactive with a cell that is allogeneic
to the T lymphocyte.
2-3. (canceled)
4. The composition of claim 1 wherein the tumor antigen is an
ovarian tumor antigen.
5. The composition of claim 1 wherein the tumor antigen is a
melanoma antigen.
6. (canceled)
7. The composition of claim 1 wherein the chimeric receptor is a
single chain Fv receptor.
8. The composition of claim 1 wherein the allogeneic cell is an
allogeneic peripheral blood cell.
9. (canceled)
10. The composition of claim 1 wherein the chimeric receptor is
Mov-.gamma..
11. (canceled)
12. A lymphocyte comprising a T-cell receptor reactive with an
allogeneic cell and a chimeric receptor reactive with a tumor
antigen, wherein the lymphocyte is activated in vivo with the
allogeneic cell.
13.-14. (canceled)
15. The lymphocyte according to claim 12 wherein the allogeneic
cell is a peripheral blood cell.
16.-39. (canceled)
40. A pharmaceutical composition comprising: a T lymphocyte
comprising a chimeric receptor reactive with a tumor antigen and an
endogenous T-cell receptor reactive with a cell that is allogeneic
to the T lymphocyte; and a pharmaceutically acceptable carrier.
41.-43. (canceled)
44. The composition of claim 4, wherein the ovarian tumor antigen
is folate binding protein (FBP).
45. The composition of claim 1, wherein the T lymphocyte is a human
T lymphocyte.
46. The lymphocyte of claim 12, wherein the lymphocyte is a human
lymphocyte.
47. The lymphocyte of claim 12, wherein the tumor antigen is an
ovarian tumor antigen.
48. The lymphocyte of claim 47, wherein the ovarian tumor antigen
is FBP.
49. The lymphocyte of claim 12, wherein the chimeric receptor is
Mov-.gamma..
50. A pharmaceutical composition comprising the lymphocyte of claim
12 and a pharmaceutically acceptable carrier.
51. A composition comprising the lymphocytes prepared by selecting
for lymphocytes reactive with an allogeneic cell ex vivo; and
transducing the lymphocytes with a chimeric receptor gene, said
gene encoding a receptor which is reactive with a tumor
antigen.
52. A composition comprising a population of T lymphocytes
comprising (a) a chimeric receptor or T cell receptor that is
reactive with a tumor antigen, and (b) a T-cell receptor that is
reactive with an allogeneic cell, wherein the population of T
lymphocytes has been exposed to a cell that is allogeneic to an
individual or subpopulation of T lymphocytes of the population
under conditions which expand and activate the individual or
subpopulation of T lymphocytes.
53. The composition of claim 52, wherein the tumor antigen is an
ovarian tumor antigen.
54. The composition of claim 53, wherein the ovarian tumor antigen
is folate binding protein (FBP).
55. The composition of claim 52, wherein the cell is a peripheral
blood mononuclear cell, splenocyte, a dendritic cell, or a B
cell.
56. The composition of claim 52, wherein the T lymphocyte is a
human T lymphocyte.
57. The composition of claim 52, wherein the population further
comprises the cell that is allogeneic to the T lymphocytes.
58. The composition of claim 51, further comprising the cell that
is allogeneic to the lymphocytes.
Description
FIELD OF THE INVENTION
[0001] The field of the present invention relates generally to
compositions and methods for the treatment or prevention of
diseases in mammals. More specifically, this invention relates to
pre-selected dual-specificity lymphocytes having endogenous T-cell
receptors and/or chimeric T-cell receptors that recognize a strong
antigen and tumor associated antigens and to preventative,
diagnostic and therapeutic applications which employ these
lymphocytes.
BACKGROUND OF THE INVENTION
[0002] Classic modalities for the treatment of diseases such as
human cancers, autoimmune diseases, viral, bacterial, parasitic and
fungal diseases include surgery, radiation chemotherapy,
antibiotics or combination therapies. However, these therapies are
not effective against a majority of these diseases. Alternate
therapies for preventing or treating human diseases are greatly
needed. In the past decade immunotherapy and gene therapy utilizing
T-lymphocytes have emerged as new and promising methods for
treating human disease, in particular human cancers.
[0003] The T cell receptor for antigen (TCR) is responsible for the
recognition of antigen associated with the major histocompatibility
complex (MHC). The TCR expressed on the surface of T cells is
associated with an invariant structure, CD3. CD3 is assumed to be
responsible for intracellular signaling following occupancy of the
TCR by ligand.
[0004] The T cell receptor for antigen-CD3 complex (TCR/CD3)
recognizes antigenic peptides that are presented to it by the
proteins of the major histocompatibility complex (MHC). Complexes
of MHC and peptide are expressed on the surface of antigen
presenting cells and other T cell targets. Stimulation of the
TCR/CD3 complex results in activation of the T cell and a
consequent antigen-specific immune response. The TCR/CD3 complex
plays a central role in the effector function and regulation of the
immune system.
[0005] Two forms of T cell receptor for antigen are expressed on
the surface of T cells. These contain either .alpha./.beta.
heterodimers or .gamma./.delta. heterodimers. T cells are capable
of rearranging the genes that encode the .alpha., .beta., .gamma.
and .delta. chains of the T cell receptor. T cell receptor gene
rearrangements are analogous to those that produce functional
immunoglobulins in B cells and the presence of multiple variable
and joining regions in the genome allows the generation of T cell
receptors with a diverse range of binding specificities. Each
.alpha./.beta. or .gamma./.delta. heterodimer is expressed on the
surface of the T cell in association with four invariant peptides.
These are the .gamma., .delta. and .epsilon. subunits of the CD3
complex and the zeta chain. The CD3 .gamma., .delta. and .epsilon.
polypeptides are encoded by three members of the immunoglobulin
supergene family and are found in a cluster on human chromosome 11
or murine chromosome 9. The zeta chain gene is found separately
from other TCR and CD3 genes on chromosome 1 in both the mouse and
human. Murine T cells are able to generate a receptor-associated
.eta. chain through alternative splicing of the zeta mRNA
transcript. The CD3 chains and the zeta subunit do not show
variability, and are not involved directly in antigen
recognition.
[0006] All the components of the T cell receptor are membrane
proteins and consist of a leader sequence, externally-disposed
N-terminal extracellular domains, a single membrane-spanning
domain, and cytoplasmic tails. The .alpha., .beta., .gamma. and
.delta. antigen-binding polypeptides are glycoproteins. The zeta
chain has a relatively short ectodomain of only nine amino acids
and a long cytoplasmic tail of approximately 110 amino acids. Most
T cell receptor .alpha./.beta. heterodimers are covalently linked
through disulphide bonds, but many .gamma..delta. receptors
associate with one another non-covalently. The zeta chain
quantitatively forms either disulphide-linked .zeta.-.eta.
heterodimers or zeta-zeta homodimers.
[0007] Another example of a type of receptor on cells of the immune
system is the Fc receptor. The interaction of antibody-antigen
complexes with cells of the immune system results in a wide array
of responses, ranging from effector functions such as
antibody-dependent cytotoxicity, mast cell degranulation, and
phagocytosis to immunomodulatory signals such as regulating
lymphocyte proliferation, phagocytosis and target cell lysis. All
these interactions are initiated through the binding of the Fc
domain of antibodies or immune complexes to specialized cell
surface receptors on hematopoietic cells. It is now well
established that the diversity of cellular responses triggered by
antibodies and immune complexes results from the structural
heterogeneity of Fc receptors (FcRs).
[0008] FcRs are defined by their specificity for immunoglobulin
isotypes. Fc receptors for IgG are referred to as Fc.gamma.R, for
IgE as Fc.epsilon.R, for IgA as Fc.alpha.R, etc. Structurally
distinct receptors are distinguished by a Roman numeral, based on
historical precedent. Three groups of Fc.gamma.Rs, designated
Fc.gamma.RI, Fc.gamma.RII, and Fc.gamma.RIII are now recognized.
Two groups of Fc.epsilon.R have been defined; these are referred to
as Fc.epsilon.RI and Fc.epsilon.RII. Structurally related although
distinct genes within a group are denoted by A, B, C. Finally, the
protein subunit is given a Greek letter, such as
Fc.gamma.RIIIA.alpha., Fc.gamma.RIIIA.gamma..
[0009] Considerable progress has recently been made in defining the
heterogeneity for IgG and IgE Fc receptors (Fc.gamma.R,
Fc.epsilon.R) through their molecular cloning. These studies make
it apparent that Fc receptors share structurally related ligand
binding domains, but differ in their transmembrane and
intracellular domains which presumably mediate intracellular
signaling. Thus, specific Fc.gamma.Rs on different cells mediate
different cellular responses upon interaction with an immune
complex. The structural analysis of the Fc.gamma.Rs and
Fc.epsilon.RI has also revealed at least one common subunit among
some of these receptors. This common subunit is the .gamma.
subunit, which is similar to the .zeta. or .eta. chain of the
TCR/CD3, and is involved in the signal transduction of the
Fc.gamma.RIII and Fc.epsilon.RI.
[0010] The low affinity receptor for IgG (Fc.gamma.RIIIA), is
composed of the ligand binding CD16.alpha. (Fc.gamma.RIIIA.alpha.)
polypeptide associated with the .gamma. chain
(Fc.gamma.RIIIA.gamma.). The CD16 polypeptide appears as membrane
anchored form in polymorphonuclear cells and as transmembrane form
(CD16.TM.) in NK. The Fc.gamma.RIIIA serves as a triggering
molecule for NK cells.
[0011] Another type of immune cell receptor is the IL-2 receptor.
This receptor is composed of three chains, the .alpha. chain (p55),
the .beta. chain (p75) and the .gamma. chain. When stimulated by
IL-2, lymphocytes undergo proliferation and activation.
[0012] Antigen-specific effector lymphocytes, such as tumor
specific T cells (Tc), are very rare, individual-specific, limited
in their recognition spectrum and difficult to obtain against most
malignancies. Antibodies, on the other hand, are readily
obtainable, more easily derived, have wider spectrum and are not
individual-specific. The major problem of applying specific
antibodies for cancer immunotherapy lies in the inability of
sufficient amounts of monoclonal antibodies (mAb) to reach large
areas within solid tumors. In practice, many clinical attempts to
recruit the humoral or cellular arms of the immune system for
passive anti-tumor immunotherapy have not fulfilled expectations.
While it has been possible to obtain anti-tumor antibodies, their
therapeutic use has been limited so far to blood-borne tumors
[Lowder, J. N. et al. Cancer Surv. 4:359-375 (1985); Waldmann, T.
A. Science 252:1657-1662 (1991)] primarily because solid tumors are
inaccessible to sufficient amounts of antibodies [Jain, R. K. J.
Natl. Cancer Inst. 81:64-66 (1989)]. The use of effector
lymphocytes in adoptive immunotherapy, although effective in
selected solid tumors, suffers on the other hand, from a lack of
specificity (such as in the case of lymphokine-activated killer
cells (LAK cells) [Mule, J. J. et al. Science 225:1487-1489 (1984)]
which are mainly NK cells) or from the difficulty in recruiting
tumor-infiltrating lymphocytes (TILs) and expanding such specific T
cells for most malignancies [Rosenberg, S. A. et al. Science
233:1318-1321 (1986)]. Yet, the observations that TILs can be
obtained in melanoma and renal cell carcinoma tumors, that they can
be effective in selected patients and that foreign genes can
function in these cells [Rosenberg, S. A. J. Clin. Oncol.
10:180-199 (1992)] demonstrate the therapeutic potential embodied
in these cells.
[0013] A strategy which has been developed (European Published
Patent Application No. 0340793) allows one to combine the advantage
of the antibody's specificity with the homing, tissue penetration,
cytokine production and target-cell destruction of T lymphocytes
and to extend, by ex vivo genetic manipulations, the spectrum of
anti-tumor specificity of T cells. Chimeric T cell receptor (cTCR)
genes composed of the variable region domain (Fv) of an antibody
molecule and the constant region domain of the antigen-binding TCR
chains, i.e., the .alpha./.beta. or .gamma./.delta. chains have
been expressed in T cells and found to be functionally active.
Adoptive immunotherapies using tumor infiltrating lymphocytes and
IL-2 have been developed for some cancers. These therapies have
resulted in significant long-term responses in some patients with
melanoma.
[0014] In an effort to broaden the applicability of adoptive
immunotherapy to common cancers, such as, for example, ovarian,
breast and colon cancer treatments that redirect the immune
reactivity of lymphocytes to antigens recognized by monoclonal
antibodies have been developed. To do this, retroviral vectors that
encode chimeric receptor genes consisting of the variable regions
of a monoclonal antibody joined to the transmembraneous and
cytoplasmic domains of a T-cell receptor (TCR) signaling chain have
been utilized. Using this approach, the safety of the
administration of these chimeric receptor-transduced lymphocytes
has been demonstrated. However, a need for improving the
effectiveness of the chimeric receptor-transduced lymphocytes
exists.
[0015] Thus, one object of the present invention is to produce an
activated chimeric receptor-transduced lymphocyte capable of
binding to and obliterating cancer cells.
SUMMARY OF THE INVENTION
[0016] One particular object of the present invention is to
increase the effectiveness of adoptive immunotherapy by increasing
the persistence and/or activity of adoptively transferred T cells
by activating a pre-selected population of adoptively transferred
lymphocytes with in vivo immunization.
[0017] Another objective of the invention is to create dual
specific T cells by genetic modification so that each individual T
cell is reactive with both a strong antigen, such as, for example
an alloantigen or other foreign agent, and the tumor. The strong
antigen is used both to expand and activate the cells in vitro and
in vivo.
[0018] The present invention relates to a composition comprising a
population of T cells transduced with a chimeric receptor gene and
pre-selected for reactivity with a strong antigen. Another
embodiment of the present invention comprises a lymphocyte having a
TCR directed to a specific strong antigen and a chimeric T-cell
receptor directed to a tumor antigen, wherein the lymphocyte has
been activated in vivo by the strong antigen. Such cells exhibit
strong anti-tumor response and provide a recipient of such cells
with a protection from tumor challenge, i.e. prophylactic response,
and an anti-tumor treatment.
[0019] The method of treating a patient with
therapeutically-activated dual-specificity lymphocytes comprises
the steps of expanding a patient's lymphocytes with one or more
specific strong antigens ex vivo, transducing the lymphocytes with
a chimeric receptor gene, introducing the transduced lymphocytes
into the patient and immunizing the patient with the strong
antigents) in vivo. A preferred embodiment of the present method
utilizes an alloantigen as the strong antigen. Another preferred
embodiment utilizes a virus or other foreign antigen as the strong
antigen.
[0020] The present invention also relates to a method of treating a
patient with dual specificity lymphocytes having reactivity to one
or more pre-selected strong antigens comprising the steps of
administering an effective amount of such lymphocytes to a patient
and immunizing the patient with the strong antigen.
[0021] The present invention relates to activated dual specific
lymphocytes containing chimeric genes suitable to endow lymphocyte
cells with antibody-type specificity and T-cell receptors specific
for one or more pre-selected strong antigens. Various types of
lymphocytes are suitable, for example, natural killer cells, helper
T cells, suppressor T cells, cytotoxic T cells, lymphokine
activated cells, subtypes thereof and any other cell type which can
express chimeric receptor chain.
[0022] The present invention further relates to pharmaceutical,
prophylactic and curative compositions containing an effective
quantity of such cells.
DESCRIPTION OF THE DRAWINGS
[0023] FIG. 1 shows a model of the dual-specific T cell created by
genetic modification such that each individual T cell has
specificity for both the strong antigen/immunogen and tumor. The
chimeric receptor enables tumor recognition and comprises
single-chain antibody variable regions (scFv) connected to TCR
signaling chains, such as the .gamma. chain of the Fc receptor.
[0024] FIG. 2 shows the results of treating 8 advanced ovarian
cancer patients with MOv-PBL infusion. Specifically, treatment was
measured by the percentage of circulating MOv-.gamma. transduced
lymphocyte cells following MOv-PBL infusion.
[0025] FIGS. 3A and 3B show the in vivo effects of allogeneic
immunization of adoptively transferred T cells in mice spleen,
lung, and blood upon immunization with allo-splenocytes (A) and
alto-DC (dendritic cells; B) as a measure of Thy 1.1 cells in
tissue.
[0026] FIG. 4 shows the phenotypic results of dual specific mouse T
cells, where these T cells express the chimeric MOv-y.
[0027] FIG. 5 shows that mice are protected against tumor challenge
when infused with dual specific T cells followed by immunization
with allogeneic splenocytes.
[0028] FIG. 6 shows a time course graph of the adoptive transfer of
dual specific T cells followed by immunization treatment of
established subcutaneous tumor in immunodeficient mice. The results
show that dual specific T cells inhibit tumor growth and that the
effect is augmented by immunization.
[0029] FIG. 7 demonstrates that dual specific MOv-.gamma.
transduced human T cells capable of recognizing both allogeneic
cells and ovarian cancer cells can be generated in vitro by using
PBMC from patients (363 and 399), transducing with MOv-y, and
stimulating with PBMC from donor (269). The graph shows that
transduced and non transduced cells released GM-CSF in response to
donor 269 PBMC. In addition, transduced patient (363 and 399) cells
released significant amounts of GM-CSF in response to IGROV,
indicating that these transduced T cells were allogeneic- and
IGROV-reactive.
[0030] FIGS. 8A-8F shows the phenotypic results of the bulk
population of T cells from patient 399 anti-269 (A-C) and of
patient 363 anti-269 (D-F), where 8C and 8F demonstrate that the T
cells express the chimeric MOv-.gamma. receptor.
[0031] FIG. 9 shows the functional assay results from bulk
MOv-.gamma. transduced T cells of patient 410, where T cells are
both allo- and IGROV-reactive as measured by GM-CSF release
(pg/ml).
[0032] FIGS. 10A-B show the phenotypic results of bulk MOv-y
transduced T cells of patient 410 (anti-556 donor), where the T
cells are primarily CD4+ and do in fact express the chimeric
MOv-.gamma. receptor.
[0033] FIGS. 11A-11J show the phenotypic results of individual
daughter clones from the bulk MOv-.gamma. transduced T cells of
patient 410 (anti-556 donor). FIGS. 11A-11E show that the T cells
express the chimeric MOv-.gamma. receptor, as demonstrated by the
shift in peak on the X-axis. FIGS. 11F-11J demonstrate by FACS
whether the clone is CD4 or CD8.
[0034] FIGS. 12A-12D show growth curve analysis of responder cells
transduced with dual specific T cells following stimulation with
various allogeneic cell types (PBMC, DC, or B cells) and control at
varying stimulator:responder ratios.
[0035] FIGS. 13A-13D show growth curve analysis of responder cells
transduced with dual specific T cells following restimulation with
various allogeneic cell types (PBMC, DC, or B cells) and control at
varying stimulator:responder ratios.
[0036] FIG. 14 shows growth curve analysis of alloreactive T cells
in MLR with various concentrations of IL-2.
[0037] FIG. 15 shows the MFG-MOv-.gamma.-I-N retroviral vector.
DETAILED DESCRIPTION OF THE INVENTION
[0038] For the purpose of a more complete understanding of the
invention, the following definitions are described herein. Nucleic
acid sequences include, but are not limited to, DNA, RNA or cDNA.
Substantially homologous as used herein refers to substantial
correspondence between the nucleic acid sequence for the V-J or
V-D-J junctional sequences for the .alpha. and .beta. chains of the
tumor antigen specific T-cell receptors provided herein and that of
any other nucleic acid sequence. By way of example, substantially
homologous means about 50-100% homology, preferably by about
70-100% homology, and most preferably about 90-100% homology
between the nucleic acid sequences and that of any other nucleic
acid sequence. In addition, substantially homologous as used herein
also refers to substantial correspondence between the amino acid
sequence of the V-J or V-D-J junctional sequences of the antigen
specific T-cell receptors provided herein and that of any other
amino acid sequence.
[0039] Major Histocompatibility Complex (MHC) is a generic
designation meant to encompass the histo-compatibility antigen
systems described in different species including the human
leukocyte antigens (HLA). The term cancer includes but is not
limited to, melanoma, epithelial cell derived cancers, lung cancer,
colon cancer, ovarian cancer, breast cancer, kidney cancer,
prostate cancer, brain cancer, or sarcomas.
[0040] The term melanoma includes, but is not limited to,
melanomas, metastatic melanomas, melanomas derived from either
melanocytes or melanocyte related nevus cells, melanocarcinomas,
melanoepitheliomas, melanosarcomas, melanoma in situ, superficial
spreading melanoma, nodular melanoma, lentigo maligna melanoma,
acral lentiginous melanoma, invasive melanoma or familial atypical
mole and melanoma (FAM-M) syndrome. The aforementioned cancers can
be treated, assessed or diagnosed by methods described in the
present application.
[0041] The lymphocytes of the present invention are pre-selected
for TCRs having reactivity with specific antigens. These antigens
are preferably strong antigens. The term "strong antigen" as it is
referred to herein relates to an antigen capable of inducing
proliferation of pre-selected adoptively transferred T cells.
Examples of such antigens include but are not limited to
alloantigens, viral agents and other foreign agents. Allogeneic
agents or "alloantigens" are antigens derived from genetically
non-identical members of the same species. Allogeneic tissues,
cells, proteins, peptides, nucleic acids and/or other cellular
components may be used to select an individual or subpopulation of
lymphocytes. Examples of viral agents are well-known in the art,
and include, but are not limited to, Epstein Barr virus and the
Flu-virus and proteins, peptides, nucleic acids and other cellular
components derived therefrom. Examples of other strong antigens
include foreign proteins such as serum proteins from other species
including bovine.
[0042] "Dual specificity lymphocytes" as that phrase is used herein
refers to lymphocytes capable of reacting with both a tumor antigen
and a pre-selected strong antigen. The tumor antigen reactivity may
be conferred by genetically modifying lymphocytes with a chimeric T
cell receptor gene encoding a binding site for the tumor antigen.
Tumor antigen reactivity may also be conferred by native TCR
itself. Reactivity with the pre-selected strong antigen(s) is
preferably conferred by in vitro expansion of the isolated
population of lymphocytes by specific T cell activation using one
or more pre-selected strong antigens.
[0043] "Chimeric receptor gene" refers to any receptor gene
encoding a protein containing an extracellular recognition/binding
site and transmembrane and intracellular portions capable of
translating the binding of a ligand to the recognition site to
specific intracellular activities. Preferably, the chimeric
receptor gene encodes sequences for T-cell receptors or parts
thereof which recognize tumor associated antigens and/or function
to translate extracellular/cytoplasmic signal to intracellular
activities in T-cells. One example of such a chimeric receptor gene
encodes a single chain variable region from a monoclonal antibody
joined to the Fc receptor chain capable of mediating T-cell
receptor signal transduction. Another preferred chimeric receptor
comprises an antibody variable region joined to the cytoplasmic
region of CD28 from a T cell or a similar region which can provide
a T cell with co-stimulation signals.
[0044] Additional examples of immune cell trigger molecules are any
one of the IL-2 receptor (IL-2R) p55 (.alpha.) or p75 (.beta.) or
.gamma. chains, especially the p75 and .gamma. subunits which are
responsible for signaling T cell and NK proliferation.
[0045] Further candidate receptor molecules for creation of scFv
chimeras in accordance with the present invention include the
subunit chains of Fc receptors. In the group of NK-stimulatory
receptors, the most attractive candidates are the .gamma.- and
CD16.alpha.-subunits of the low affinity receptor for IgG,
Fc.gamma.RIII. Occupancy or cross-linking of Fc.gamma.RIII (either
by anti-CD16 or through immune complexes) activates NK cells for
cytokine production, expression of surface molecules and cytolytic
activity [Unkeless, J. C. et al., Annu. Rev. Immunol. 6:251-281
(1988); Ravetch, J. V. and Kinet, J. P. Annu. Rev. Immunol.
9:457-492 (1991)]. In NK cells, macrophages, and B and T cells, the
Fc.gamma.RIII appears as a heterooligomeric complex consisting of a
ligand-binding a chain associated with a disulfide-linked .gamma.
or zeta chain. The Fc.gamma.RIIIA signalling gamma chain
[Wirthmuller, V. et al., J. Exp. Med. 175:1381-1390 (1992)] serves
also as part of the Fc.epsilon.RI complex, where it appears as a
homodimer, is very similar to the CD3 zeta chain, and in fact can
form heterodimers with it in some cytolytic T lymphocytes (CTL) and
NK cells [Orloff, D. G., et al. Nature (London) 347:189-191 (1990);
Lanier, L. G., et al. J. Immunol. 146:1571-1576 (1991); Vivier, E.,
et al. J. Immunol. 147:4263-4270 (1991)]. Most recently prepared
chimeras between these polypeptides and the CD4 [Romeo, C. and
Seed, B. Cell 64:1037-1046 (1991)], the CD8 [Irving, B. A. and
Weiss, A. Cell 64:891-901 (1991)], IL-2 receptor chain [Letourneur,
F. and Klausner, R. D. Proc. Natl. Acad. Sci. USA 88:8905-8909
(1991)] or CD16 extracellular domains, proved to be active in
signaling T cell stimulation even in the absence of other TCR/CD3
components.
[0046] In one embodiment, the chimeric receptor genes encode amino
acid sequences which provide for the V-J or V-D-J junctional
regions or parts thereof for the alpha and beta chains of the
T-cell receptor which recognize tumor associated antigens. In
general, the chimeric T-cell receptors recognize or bind tumor
associated antigens presented in the context of MHC Class I. Many
different tumor associated antigens are known to the skilled
artisan. A tumor antigen can be defined as a molecule that can be
used to target therapy against a tumor and includes those antigens
only found on tumor cells (i.e. tumor specific), those which are
expressed on tumor cells and on limited normal tissues, i.e.
differentiation antigens (including cancer-testis antigens) and
those which are over-expressed on tumor cells compared to the
expression on a wide variety of normal tissues (i.e. over-expressed
antigens). Examples of over-expressed antigens include, but are not
limited to, Folate binding protein (FBP), Erb-B2, GD-2, HMW-MAA,
G250, TAG-72, NY-ESO-1, carcino-embryonic antigen and
alpha-fetoprotein. Differentiation antigens include, for example,
Tyrosinase, MART-1, MAGE and gp100 of melanoma. Tumor-specific
antigens include, for example, mutant Ras, mutant p53, mutant
Erb-B2 of a wide variety of tumors including breast and colon. Any
of these tumor antigens can serve as the binding agent for the TCR
or chimeric receptor. The choice of which antigen to target is
within the skill of the ordinary artisan, and is based upon the
specific tumor being targeted.
[0047] In one preferred embodiment, the tumor associated antigens
recognized by the receptors of this invention are melanoma
antigens. By way of example, melanoma specific T-cell receptors may
recognize melanoma antigens in the context of HLA-A2.1 or HLA-A1.
Examples of melanoma antigens which are recognized by the chimeric
receptors include, but are not limited to, MART-1, or peptides
thereof or gp-100 or peptides thereof. In a preferred embodiment
the chimeric receptor recognizes or binds to the MART-1 peptide, in
particular epitopes M9-1 (TTAEEAAGI), M9-2 (AAGIGILTV), M10-3
(EAAGIGILTV), and M10-4 (AAGIGILTVI) (shown in single letter amino
acid code) or gp-100 peptide epitopes.
[0048] The chimeric receptor is provided as a recombinant DNA
molecule comprising all or part of the T-cell receptor nucleic acid
sequence and a vector. The nucleic acid sequences encoding the
.alpha. and .beta. chains of a T-cell receptor of the present
invention may be placed in a single expression vector.
Alternatively the .alpha. chain and the .beta. chain may each be
placed in a separate expression vector. Expression vectors suitable
for use in the present invention may comprise at least one
expression control element operationally linked to the nucleic acid
sequence. The expression control elements are inserted in the
vector to control and regulate the expression of the nucleic acid
sequence. Examples of expression control elements include, but are
not limited to, lac system, operator and promoter regions of phage
lambda, yeast promoters and promoters derived from polyoma,
adenovirus, retrovirus, cytomegalovirus (CMV), SR.alpha., MMLV,
SV40 or housekeeping promoters such as phosphoglycerol kinase (PGK)
and .beta. actin. Additional preferred or required operational
elements include, but are not limited to, leader sequences,
termination codons, polyadenylation signals and any other sequences
necessary or preferred for the appropriate transcription and
subsequent translation of the nucleic acid sequence in the host
system. It will be understood by one skilled in the art that the
correct combination of required or preferred expression control
elements will depend on the host system chosen. It will further be
understood that the expression vector may contain additional
elements necessary for the transfer and subsequent replication of
the expression vector containing the nucleic acid sequence in the
host system. Examples of such elements include, but are not limited
to, origins of replication and selectable markers and long terminal
repeats (LTR) and internal ribosomal entry site (IRES). The
expression vector may also include a leader peptide sequence. It
will further be understood by one skilled in the art that such
vectors are easily constructed using conventional methods [Ausubel
et al., (1987) in "Current Protocols in Molecular Biology", John
Wiley and Sons, New York, N.Y.] or commercially available.
[0049] Alternatively, the chimeric receptor gene may comprise a
first gene segment encoding the single chain Fv receptor (scFv) of
a specific antibody, i.e., DNA sequences encoding the variable
regions of the heavy and light chains (V.sub.H and V.sub.L,
respectively) of the specific antibody, linked by a flexible
linker, and a second gene segment which comprises a DNA sequence
encoding partially or entirely the transmembrane and cytoplasmic,
and optionally the extracellular, domains of a
lymphocyte-triggering molecule corresponding to a lymphocyte
receptor or part thereof. Thus, the scFvR design may be
advantageous over the two-chain version of the receptor. It
requires the expression of only one gene instead of the gene pair
required for the cTCR, thereby providing simpler construction and
transfection.
[0050] The scFv domain may preferably be joined to the immune cell
triggering molecule such that the scFv portion will be
extracellular when the chimera is expressed. This is accomplished
by joining the scFv either to the very end of the transmembrane
portion opposite the cytoplasmic domain of the trigger molecule or
by using a spacer which is either part of the endogenous
extracellular portion of the triggering molecule or from other
sources. The chimeric molecules of the present invention have the
ability to confer on the immune cells on which they are expressed
MHC nonrestricted antibody-type specificity. Thus, a continuous
polypeptide of antigen binding and signal transducing properties
can be produced and utilized as a targeting receptor on immune
cells. In vivo, cells expressing these genetically engineered
chimeric receptors will home to their target, will be stimulated by
it to attract other effector cells, or, by itself, will mediate
specific destruction of the target cells. In a preferred
embodiment, the target cells are tumor cells and the scFv domain is
derived from an antibody specific to an epitope expressed on the
tumor cells. It is expected that such anti-tumor cytolysis can also
be independent of exogenous supply of IL-2, thus providing a
specific and safer means for adoptive immunotherapy.
[0051] Besides the specific receptor chains specifically mentioned
herein, the single chain Fv chimeras can be made by joining the
scFv domain with any receptor or co-receptor chain having a similar
function to the disclosed molecules, e.g., derived from
granulocytes, B lymphocytes, mast cells, macrophages, etc. The
distinguishing features of desirable immune cell trigger molecules
comprise the ability to be expressed autonomously (i.e., as a
single chain), the ability to be fused to an extracellular domain
such that the resultant chimera is expressed on the surface of an
immune cell into which the corresponding gene was genetically
introduced, and the ability to take part in signal transduction
programs secondary to encounter with a target ligand.
[0052] The construction options for the production of chimeric
T-cell receptor genes and their corresponding proteins can be found
in U.S. Pat. No. 5,830,755 and U.S. application Ser. No.
08/547,263, both of which are incorporated herein by reference in
toto. In addition, Hwu et al (Can. Res. (1995) 55:3369-3373) and
Wang et al (Nat. Med. (1998) 492:168) describe details of
introducing a chimeric receptor gene into cells and treating tumors
therewith. These references are incorporated herein by
reference.
[0053] Specific expansion and specific activation of the T cells
containing the chimeric T-cell receptor gene are important parts of
the present invention. In one embodiment, the specific expansion
step amplifies an individual or a subpopulation of T cells whose
endogenous TCR is directed to the strong antigen(s) used to expand
the T cells. In this way, T cells which react with the antigen(s)
are selected out and amplified from a mixed population of T cells
originally obtained from the patient. The expanded lymphocytes are
transduced with a chimeric receptor gene. These pre-selected,
transduced T cells are introduced into a patient, and the patient
is immunized with the strong antigen(s). This in vivo immunization
step serves to activate the pre-selected adoptively transferred T
cells and to target the lymphocytes to the cancer antigen through
the chimeric receptor.
[0054] In a preferred embodiment of the invention, patients undergo
leukapheresis to obtain peripheral blood lymphocytes (PBL). The
lymphocytes are separated from other cells. Various methods of
separation are known to the artisan and can be utilized. One
preferred separation technique employs centrifugation on a Ficoll
cushion. The preferred host cells transformed with all or part of
the chimeric receptor nucleic acid sequences may include
JURKAT-cells, T-lymphocytes, peripheral blood cells such as
peripheral blood lymphocytes (PBL) and peripheral blood mononuclear
cells (PBMC), dendritic cells, monocytes, stem cells, natural
killer (NK) cells or macrophages.
[0055] Candidate immune cells to be endowed with antibody
specificity using this approach are: NK cells, lymphokine-activated
killer cells (LAK), cytotoxic T cells, helper T cells, and the
various subtypes of the above. These cells can execute their
authentic natural function and can serve, in addition, as carriers
of foreign genes designated for gene therapy, and the chimeric
receptor shall serve in this case to direct the cells to their
target. This approach can be applied also to anti-idiotypic
vaccination by using helper T cells expressing chimeric receptors
made of Fv of antiidiotypic antibodies.
[0056] The cells are activated with one or more preselected
antigens. Any strong antigen, i.e. one that is capable of inducing
proliferation of the adoptively transferred lymphocytes, may be
utilized for the activation/selection step. The lymphocytes are
preferably exposed to the strong antigen for greater than one hour
in the case of proteins and virus or for at least 24 hours,
preferably, continuously, for allogeneic cells as strong antigens.
The strong antigen is provided up to a concentration of 1
millimolar when proteins, peptides or cellular components are used
or at a ratio of one dual specific T-cell to 1-1000 infectious
viral particles or between 1 and 100 allogeneic cells per each
dual-specific T-cell. A combination of several stimuli may
optionally be included in the activation/selection mixture. One
preferred embodiment utilizes a donor's PBLs as an allogeneic
agent. When donor PBLs are used, selection is carried out by
co-culture of irradiated donor PBMC with patient PBMC at a ratio
preferably with the range of 2:1 to 5:1.
[0057] These cells are transduced with a chimeric receptor gene.
"Transduction" or introduction of foreign DNA into the immune cells
may be carried out by any manner known in the art, such as, for
example, microinjection, electroporation, transduction, retroviral
transduction or transfection using DEAE-dextran, lipofection,
calcium phosphate, particle bombardment mediated gene transfer or
direct injection of nucleic acid sequences encoding the chimeric
receptors or other procedures known to one skilled in the art
[Sambrook et al. (1989) in "Molecular Cloning. A Laboratory
Manual", Cold Spring Harbor Press, Plainview, N.Y.]. One preferred
method of transduction follows the method described in Hwu, et al.,
(1993) J. Immunol. 150:4104-4115. One preferred method of
transduction resuspends the lymphocyte preparation in a retroviral
supernatant at a concentration range of 1.times.10.sup.2 to
1.times.10.sup.1.degree. per ml, more preferably at a range of
1.times.10.sup.4 to 1.times.10.sup.8, most preferably at a
concentration of 1.times.10.sup.6. Transduction may preferably be
followed by a selection step, such as for example using an
antibiotic selection marker on the chimeric receptor gene
construct, such as the neomycin resistance gene.
[0058] The preselected transduced lymphocytes may be cultured for
several days. Between days 14-21, it may be desirable to screen the
cells for specific cytokine release against ovarian tumor antigens
and/or assay for phenotype integrity. At this time, it may also be
desirable to restimulate the lymphocyte population with the strong
antigen. Restimulation using a strong antigen is preferably carried
out at a similar concentration as used for the initial stimulation
for a similar time period. If donor cells are used as the
allogeneic agent, restimulation is preferably carried out at a
ratio of 0.5:1 to 4:1, more preferably at a ratio of 1:1 to 2:1
(donor:patient). These cells can be directly reintroduced into the
patient or can be frozen for future use, i.e. for subsequent
administrations to this patient.
[0059] Upon expansion of lymphocytes in IL-2 containing media,
patients receive preselected transduced lymphocytes intravenously.
Optionally, the patient may also receive IL-2, preferably after the
lymphocyte infusion. It is preferable that the IL-2 be provided at
a dosage range of 1200 IU/kg to 1,200,000 IU/kg, more preferably at
120,000 IU/kg every 12 hours. After the first administration,
patients may again receive preselected, transduced lymphocytes
intravenously with or without similar doses of IL-2. Dual
specificity lymphocytes are administered at a dosage range of
1.times.10.sup.6 to 1.times.10.sup.15, more preferably
1.times.10.sup.8 to 1.times.10.sup.11, most preferably
3.times.10.sup.9 to 5.times.10.sup.1.degree. cells. Further details
on dosage and frequency of cells are provided in U.S. Pat. No.
5,399,346, which is incorporated herein by reference, in toto.
[0060] The present invention provides a method of inhibiting or
preventing the growth of tumor cells by exposing tumor cells to the
dual specificity lymphocytes provided herein. The dual specificity
lymphocytes may be used for either prophylactic or therapeutic
purposes. When provided prophylactically, the dual specificity
lymphocytes is provided in advance of any evidence or symptom in
the mammal due to cancer, in particular, melanoma. The prophylactic
use of the dual specificity lymphocytes serves to prevent or
attenuate cancer, in particular melanoma, in a mammal. When
provided therapeutically, dual specificity lymphocytes are provided
after the onset of the disease in the mammal. The therapeutic
administration of the dual specificity lymphocytes serves to
attenuate the disease.
[0061] Cell-based immunotherapy currently utilizes the adoptive
transfer to patients of tumor specific TIL which are generically
expanded ex vivo [Rosenberg S. A. 1992. J. Clin. Oncol., 10:80;
Rosenberg S. A., et al. N. Engl. J. Med., 319:1676; Hwu P., et al.
1993. J. Exp. Med., 178:361]. T-cell specificity may be redirected
by combination of the in vitro transfer of the nucleic acid
sequences encoding the tumor associated antigen specific T-cell
receptors and selective expansion of the lymphocytes with one or
more strong antigens. By way of example, a heterogenous population
of T-cells, such as TIL, may be made more effective by conferring
anti-tumor reactivity to non-specific T-cell populations within the
TIL, and selective expansion of T lymphocytes to amplify T
lymphocytes reactive with one or more pre-selected strong
antigens.
[0062] Cells that can be modified to produce dual specificity
lymphocytes include, but is not limited to, lymphocytes, cytotoxic
T-lymphocytes, hematopoietic stem cells, monocytes, stem cells,
peripheral blood and natural killer cells. In a preferred
embodiment, T-cells can be genetically modified to express the
tumor antigen specific T-cell receptors. Constructs containing all
or parts of the nucleic acid sequences encoding the chimeric T-cell
receptors may be introduced in T-lymphocytes by conventional
methodology. By way of example such methods include, but are not
limited to, calcium phosphate transfection, electroporations,
lipofections, transduction by retroviruses, injection of DNA,
particle bombardment and mediated gene transfer use of a retroviral
vector, viral vectors, transduction by viral co-culturing with a
producer cell line. Preferably, the construct or constructs
carrying the nucleic acid sequences encoding the chimeric T-cell
receptors are introduced into the T-cells by transduction with
viral supernatant or co-cultivation with a retroviral producer cell
line. Examples of vectors that may be used include, but are not
limited to, defective retroviral vectors, adenoviral vectors,
vaccinia viral vectors, fowl pox viral vectors, or other viral
vectors [Mulligan, R. C., (1993) Science 260:926-932]. Eukaryotic
expression vectors G1EN [Treisman, J., et al., Blood, 85:139;
Morgan et al. (1992) Nucleic Acids Res. 20:1293-1299], LXSN
[Miller, A. D., et al. Methods Enzymol., 217:581-599 (1993);
Miller, A. D., et al. BioTechniques, 7:980-988 (1989); Miller, A.
D., et al., Mol. Cell Biol., 6:2895-2902 (1986); Miller, A. D.
Curr. Top. Microbiol. Immunol., 158:1-24 (1992)], and SAM-EN
[Treisman, J., et al., Blood, 85:139] may also be used. Individual
constructs carrying the genes coding for the alpha and beta chains
that comprise the receptor may be introduced into the T-lymphocytes
or alternatively, an individual construct carrying the nucleic acid
sequences encoding for both the .alpha. and .beta. chains of the
T-cell receptor may be in a single construct. Preferably, a
retroviral vector, for example a vector with the murine moloney
leukemia viral LTR promoting transcription of the T-cells receptor
genes is used. In a preferred embodiment non-replicating retroviral
vectors are used. Alternatively, the genes can be expressed using
an internal housekeeping promoter, such as that from the
phosphoglycerol kinase (PGK) gene.
[0063] The .alpha. and .beta. chains of the T-cell receptor may
either be expressed on separate retroviral vectors, or on the same
retroviral vector, separated by an internal ribosomal entry site
(IRES) [Treisman, J., et al., Blood, 85:139; Morgan, R. A., et al.,
Nucleic Acids. Res., 20:1293-1299 (1992)]. Using an IRES-containing
vector, allows both T-cell receptor genes to be translated from a
single RNA message. Examples of where T-lymphocytes can be
isolated, include but are not limited to, peripheral blood cell
lymphocytes (PBL), lymph nodes, or tumor infiltrating lymphocytes
(TIL), or blood. Such lymphocytes can be isolated from the
individual to be treated or from a donor by methods known in the
art and cultured in vitro [Kawakami, Y. et al. (1989) J. Immunol.
142: 2453-3461]. Alternatively, a single chain Fv receptor gene may
be constructed and used as the chimeric receptor gene.
[0064] The T-cells may be incubated with a retroviral producer cell
line carrying retroviral expression vectors or with viral
supernatant. Viability of the lymphocytes may be assessed by
conventional methods, such as trypan blue dye exclusion assay. The
genetically modified lymphocytes expressing the desired melanoma
specific T-cell receptor may then be administered to a mammal,
preferably a human, in need of such treatment in a therapeutically
effective amount. The dosing regimes or ranges of lymphocytes used
in the conventional tumor infiltrating lymphocyte (TIL) therapy
[Rosenberg, et al. (1994) J. Natl. Canc. Inst., Vol. 86:1159] may
be used as general guidelines for the doses or number of
T-lymphocytes to be administered to mammal in need of such
treatment. By way of example, a range of about 1.times.10.sup.10 to
about 1.times.10.sup.11 T-cells for each cycle of therapy may be
administered in the methods provided herein. Examples of how these
antigen specific T-cells can be administered to the mammal include
but are not limited to, intravenously, intraperitoneally or
intralesionally. Parameters that may be assessed to determine the
efficacy of these transduced T-lymphocytes include, but are not
limited to, production of immune cells in the mammal being treated
or tumor regression. Conventional methods are used to assess these
parameters. Such treatment can be given in conjunction with
cytokines or gene modified cells [Rosenberg, S. A. et al. (1992)
Human Gene Therapy, 3: 75-90; Rosenberg, S. A. et al. (1992) Human
Gene Therapy, 3: 57-73] chemotherapy or active immunization
therapies. One of skill in the art will appreciate that the exact
treatment schedule and dosages, or amount of T-lymphocytes to be
administered may need to be optimized for a given individual.
[0065] This invention also relates to pharmacological compositions
comprising the dual specificity lymphocytes. The formulations of
the present invention, both for veterinary and for human use,
comprise each component individually or as a composition as
described above, together with one or more pharmaceutically
acceptable carriers and, optionally, other therapeutic ingredients.
The carrier(s) must be "acceptable" in the sense of being
compatible with the other ingredients of the formulation and not
deleterious to the recipient thereof. The formulations may
conveniently be presented in unit dosage form and may be prepared
by any method known in the pharmaceutical art.
[0066] Preparation of the Pharmaceutical Compositions Include the
step of bringing into association the active ingredient with the
carrier which constitutes one or more accessory ingredients. In
general, the formulations are prepared by uniformly and intimately
bringing into association the active ingredient with liquid
carriers or finely divided solid carriers or both, and then, if
necessary, shaping the product into the desired formulation.
[0067] Formulations suitable for intravenous intramuscular,
subcutaneous, or intraperitoneal administration conveniently
comprise sterile aqueous solutions of the active ingredient with
solutions which are preferably isotonic with the blood of the
recipient. Such formulations may be conveniently prepared by
dissolving solid active ingredient in water containing
physiologically compatible substances such as sodium chloride (e.g.
0.1-2.0M), glycine, and the like, and having a buffered pH
compatible with physiological conditions to produce an aqueous
solution, and rendering said solution sterile. These may be present
in unit or multi-dose containers, for example, sealed ampoules or
vials.
[0068] The formulations of the present invention may incorporate a
stabilizer. Illustrative stabilizers are polyethylene glycol,
proteins, saccharide, amino acids, inorganic acids, and organic
acids which may be used either on their own or as admixtures. These
stabilizers are preferably incorporated in an amount of 0.11-10,000
parts by weight per part by weight of each component or the
composition. If two or more stabilizers are to be used, their total
amount is preferably within the range specified above. These
stabilizers are used in aqueous solutions at the appropriate
concentration and pH. The specific osmotic pressure of such aqueous
solutions is generally in the range of 0.1-3.0 osmoles, preferably
in the range of 0.8-1.2. The pH of the aqueous solution is adjusted
to be within the range of 5.0-9.0, preferably within the range of
6-8. In formulating each component separately or as a composition
of the present invention, anti-adsorption agent may be used.
[0069] Additional pharmaceutical methods may be employed to control
the duration of action. Controlled release preparations may be
achieved through the use of polymer to complex or absorb the cells
or their derivatives. The controlled delivery may be exercised by
selecting appropriate macromolecules (for example polyester,
polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate,
methylcellulose, carboxymethylcellulose, or protamine sulfate) and
the concentration of macromolecules as well as the methods of
incorporation in order to control release. Another possible method
to control the duration of action by controlled-release
preparations is to incorporate the 9-cis-retinoic acid or
derivatives thereof alone or in combination with antineoplastic
agents thereof into particles of a polymeric material such as
polyesters, polyamino acids, hydrogels, poly(lactic acid) or
ethylene vinylacetate copolymers. Alternatively, instead of
incorporating these agents into polymeric particles, it is possible
to entrap these materials in microcapsules prepared, for example,
by coacervation techniques or by interfacial polymerization, for
example, hydroxymethylcellulose or gelatin-microcapsules and
poly(methylmethacylate) microcapsules, respectively, or in
colloidal drug delivery systems, for example, liposomes, albumin
microspheres, microemulsions, nanoparticles, and nanocapsules or in
macroemulsions.
[0070] When oral preparations are desired, the component may be
combined with typical carriers, such as lactose, sucrose, starch,
talc magnesium stearate, crystalline cellulose, methyl cellulose,
carboxymethyl cellulose, glycerin, sodium alginate or gum arabic
among others.
[0071] The administration of the compositions or of each individual
component of the present invention may be for either a prophylactic
or therapeutic purpose. The methods and compositions used herein
may be used alone in prophylactic or therapeutic uses or in
conjunction with additional therapies known to those skilled in the
art in the prevention or treatment of cancer. Alternatively the
methods and compositions described herein may be used as adjunct
therapy. Veterinary uses are also intended to be encompassed by
this invention.
[0072] All references cited herein, including journal articles or
abstracts, published or corresponding U.S. or foreign patent
applications, issued U.S. or foreign patents, or any other
references, are entirely incorporated by reference herein,
including all data, tables, figures, and text presented in the
cited references. Additionally, the entire contents of the
references cited within the references cited herein are also
entirely incorporated by reference.
[0073] Reference to known method steps, conventional methods steps,
known methods or conventional methods is not in any way an
admission that any aspect, description or embodiment of the present
invention is disclosed, taught or suggested in the relevant
art.
[0074] The invention will now be illustrated by the following
non-limiting examples.
EXAMPLES
Example 1
Ineffective Treatment of Cancer Patients
[0075] Previously, chimeric receptors against ovarian cancer
(MOv-.gamma.) were found to be functional in primary T cells in
vitro and in vivo [Hwu, P., et al. J. Exp. Med., 178:361-366, 1993;
Hwu, P., et al., Cancer Res., 55:3369-3373, 1995]. The effects of
treating eight patients with advanced ovarian cancer with T cells
transduced with chimeric receptor genes derived from a monoclonal
antibody against ovarian cancer, MOv-18 alone, and without any
specificity were observed. Tumor-infiltrating lymphocytes (TIL) or
anti-CD3 stimulated peripheral blood lymphocytes (PBL) retrovirally
transduced with the MOv-18 chimeric receptor gene (MOv-7) were
generated in large numbers of MOv-PBL which remained highly
reactive against ovarian cancer cells in vitro prior to infusion.
Patients were treated with up to 5.times.10.sup.1.degree.
transduced PBL for CD3 in combination with systemic IL-2 (120,000
CU/kg). The results of this clinical trial demonstrated that cells
were directed to lung, liver, and spleen, but did not specifically
localize at tumor sites. Despite specific in vitro reactivity of
MOv-PBL against ovarian cancer cells, none of the patients
responded to the lymphocyte infusion. The number of circulating
transduced cells following MOv-PBL infusion was determined. Between
4-6 days following MOv-PBL infusion, between 0.01 and 1%
circulating transduced cells were detected; however, between 12-31
days, the majority of transduced cells were undetectable. FIG. 2
shows the percentage of circulating transduced cells during the
course of the treatment after MOv-PBL infusion.
Example 2
Functionality of MOv-PBL after Ineffective Treatment of Cancer
Patients
[0076] In order to address the question as to why patients
transduced with chimeric receptor genes did not respond to
treatment although 10% of transduced cells were found circulating
in one patient's PBMC analyzed after 5 days post MOv-PBL infusion,
the functionality of MOv-PBL after cell transfer was determined.
Fresh uncultured PBMC from the day 5 post MOv-PBL infusion time
point were co-cultured with ovarian cancer cells or melanoma cells
(888 mel or 1300 mel). Supernatants were assayed for IFN-.gamma. by
enzyme-linked immunosorbent assay (ELISA) and lysates were analyzed
for IFN-.gamma. mRNA using Taqman. No significant IFN-.gamma.
release was seen using the fresh day 5 PBMC. To reisolate the
adoptively transferred MOv-PBL, the PBMC from day 5 were cultured
in G418 (for neomycin resistant selection), anti-CD3, and IL-2.
After 17 days, the culture was highly enriched for reisolated
MOv-PBL (69% positive for gene) that were capable of specifically
producing large amounts of cytokine in response to ovarian tumor
cells. As measured by IFN-.gamma. release (pg/ml), Table 1 shows
that MOv-PBL retained their ability to recognize tumor after
adoptive transfer. The NV PBL group did not result in IGROV or
melanoma reactivity. The NV PBL and G418 group also did not result
in significant IGROV, 888 mel, or 1300 mel reactivity. Both
cultured MOv-PBL and the reisolated PBL were significantly
IGROV-reactive. These results indicate that MOv-PBL retained their
ability to recognize tumor after adoptive transfer, although
culturing was necessary to observe anti-tumor reactivity.
TABLE-US-00001 TABLE 1 IFN-.gamma. Release (pg/ml) GROUP IGROV 888
mel 1300 mel NV PBL 0 0 0 NV PBL + G418 0 49 0 MOv-.gamma.
transduced 3582 3 14 PBL Reisolated PBL 2912 0 192
Example 3
In Vivo Expansion of Alloreactive Cultured T Cells in Murine
Models
[0077] In order to determine the effects of allogeneic immunization
of adoptively transferred T cells, anti-allogeneic mouse (C57BL/6)
T cells were raised in a mixed lymphocyte reaction (MLR) for 7 days
and restimulated for 6 additional days. Thy 1.1+ alloreactive (H2-b
anti-H2-d) T cells were generated and expanded and 1.times.10.sup.7
cells were adoptively transferred into congenic C57BL/6 mice (Thy
1.2) by intravenous injection. The C57BL/6 mice were immunized with
allogeneic antigen presenting cells from BALB/c mice on days 2, 5,
and 8 after transfer. Where stimulators, for example, either
allogeneic splenocytes or allogeneic dendritic cells (DC), were
used to immunize the mice. Stimulators are strong antigenic agents
which activate responder cells, for example lymphocytes. There were
3 mice per condition group. Tissues (spleen, lung, and blood) were
harvested on day 11 and Thy 1.1 cells were quantified following
staining and fluorescence-activated cell sorter (FACS) analysis.
The percent of Thy 1.1 cells in tissue was measured by comparing
those immunized with allogeneic splenocytes and allogeneic DC.
Adoptively transferred, cultured alloreactive T cells were found to
expand in vivo following immunization with allogeneic antigen
presenting cells and increased the survival of in vitro-cultured,
adoptively transferred allo-reactive T cells upon immunization with
allogeneic cells (FIGS. 3A and 3B).
Example 4
Generation of Dual Specificity Mouse T Cells
[0078] C57BL/6 mice T cells (2.times.10.sup.7) were raised in a
mixed leukocyte reaction (MLR) in 24 well plates and 10 CU/ml IL-2
with restimulation on day 7. G418 (0.5 mg/ml) was added for 6 days
until day 13 and assayed for MOv-'y expression and IFN-.gamma.
secretion in response to various target cells. The results of Table
2 and FIG. 4 show that dual specificity T cells expressing chimeric
MOv-.gamma. with significant anti-allogeneic and anti-FBP activity
as measured by IFN-.gamma. (pg/ml) was generated.
TABLE-US-00002 TABLE 2 Non-transduced T Media cells MOv-.gamma. T
cells Media 0 0 0 CT26 (allogeneic 0 65,200 138,700 H-2d) 24JK
(H-2b) 0 0 0 24JK-FBP 0 0 5200 888 mel 0 0 0 IGROV (ovarian 0 0
37,500 FBP+)
Example 5
Protection Against Tumor Challenge by Adoptive Transfer of Dual
Specificity T Cells
[0079] C57BL/6 mice received 1.times.10.sup.7 dual specificity
allogeneic/MOv-.gamma. T cells followed by subcutaneous
immunization with 5.times.10.sup.7 allogeneic splenocytes from
donor mice 2 days later. Seven days after immunization, mice were
challenged with 2.times.10.sup.5 24JK-FBP ovarian cancer tumor
cells subcutaneously. The 24JK is a clone from the
3-methylcholanthrene-induced, poorly immunogenic MCA 102 murine
sarcoma, where 24JK-FBP is 24JK transduced with the folate binding
protein (FBP) gene, which is expressed highly on ovarian
adenocarcinomas and MOv-.gamma. is a mAb that binds FBP. Five mice
per condition were then monitored for 20 days. FIG. 5 shows that in
vivo immunization with allogeneic splenocytes from donor mice, in
combination with administration of dual specificity T cells
protected mice much more significantly than T cells alone.
Specifically, the combined conditions result in 100% tumor-free
mice while mice infused with dual specificity T cells alone
resulted in 25% tumor-free mice.
Example 6
Treatment of Established Subcutaneous Tumor in Immunodeficient Mice
with Adoptive Transfer of Dual Specificity T Cells Followed by
Immunization
[0080] In order to determine whether the combination of adoptively
transferred dual specificity T cells and immunization with
allogeneic cells can inhibit established subcutaneous tumors, 3
RAG-1 immunodeficient knock out mice per condition were injected on
day 0 with 2.times.10.sup.5 tumor cells, specifically, 24JK and
24JK-FBP tumor cells. On day 3, mice received either
1.times.10.sup.7 dual specificity T cells, 1.times.10.sup.7
non-transduced (NV) T cells, or no treatment. Subcutaneous
immunization with 5.times.10.sup.7 allogeneic splenocytes was
performed on days 5, 8, and 11. On day 15, one mouse per group
having a middle sized tumor was sacrificed in order to determine
the effect of immunization on transferred T cell numbers. Dual
specificity T cells inhibited the tumor and this effect was
augmented by immunization. FIG. 6 shows that mice injected with
24JK-FBP tumor cells followed by transduced dual specificity T
cells and immunization or boost, resulted in the smallest tumor
size throughout the time course of 29 days.
Example 7
Generating Dual Specificity Human T Cells
[0081] Since murine studies indicated that dual specificity T cells
can be generated and functional, used for prevention, and treatment
of tumors, dual specificity human T cells were generated. On day 0,
2.times.10.sup.6 responder cells or peripheral blood mononuclear
cells (PBMC) from patients 363 and 399 were cultured in the
presence of 2.times.10.sup.5 irradiated (5 Krads) stimulator cells
or PBMC from donor 269 [Aim V medium (Life Technologies)/5% human
serum, type AB (Valley Biomedical); 100 CU IL-2/ml] per well in a
24 well plate. On day 12 patient cells were restimulated with donor
269 PBMC (5.times.10.sup.5 T cells and 2.times.10.sup.5 irradiated
stimulators/well). On days 15 and 16, cultured cells were
transduced with MOv-'y supernatant during centrifugation at 1000 g
(2700 rpm in Sorvall tabletop centrifuge for 1 hour) in the
presence of 8 .mu.g/ml polybrene, a polycation which aids in
retroviral infection. On days 18-22 cells were incubated with 0.5
mg/ml G418 (Geneticin; Life Technologies) per day for neomycin
selection. On day 27 cells were restimulated with donor 269 PBMC as
above. On day 35, the bulk population was assayed and cloned at 1
cell/well using standard surgery branch (SB) method with OKT3
stimulation and PBMC from another donor. Results indicated that
human anti-allogeneic T cells raised from PBMC 363 and 399 against
PBMC269 are both allogeneic-reactive and MOv-reactive following
transduction with chimeric MOv-.gamma. (FIG. 7). On days 49-52, the
clones were characterized. The anti-allogeneic reactivity of PBMC
399 clones as measured by GM-CSF release (pg/ml) indicated that
62.5% of the clones were allo-reactive, 23.5% of the top 17
allo-reactive clones were demonstrated to be IGROV-reactive, and
12% were both allo-reactive and IGROV-reactive. The anti-allogeneic
reactivity of PBMC 363 clones as measured by GM-CSF release
indicated that 58% of the clones were alto-reactive, 57% of the top
7 allo-reactive clones were IGROV-reactive, and 36% were both
allogeneic- and IGROV-reactive. Phenotypic characterization of the
bulk population is described by FACS analysis (FIGS. 8A-8F), where
FIGS. 8A-8C represent the phenotype for the bulk population of
patient 399 anti-269 and FIGS. 8D-8F represent the phenotype for
the bulk population of patient 363 anti-269. FIGS. 8A and 8D show
the control results using non-specific IgG2a; FIGS. 8B and 8E
describe the CD4 and/or CD8 phenotype of the population of cells;
and FIGS. 8C and 8F show the shift of the MOv antibody-stained
cells which represents the presence of the ovarian cancer
(MOv)-specific receptor on T cells.
Example 8
Generating Dual Specificity T Cells and Expanding Using the SB REP
Method
[0082] In order to determine whether or not individual T cells were
both allogeneic- and MOv-.gamma.-reactive, PBMC from patient 410
were used to generate and characterize dual specificity T cells. On
day 0, 5.times.10.sup.7 PBMC from 410 were cultured in the presence
of 2.times.10.sup.6 responders irradiated allogeneic PBMC/well from
donor 556 (AIM-V/5% human serum; 100 CU IL-2/ml; in 24 well
plates). On days 6 and 8, PBMC from 410 were transduced with MOv-y
supernatant supplemented with 8 .mu.g/ml polybrene. Plates were
centrifuged at 1000 g or 2700 rpm. On days 9-13, G418 selection was
performed using 0.5 mg/ml per day. On day 14, the bulk population
was assayed and cloned at a 1 cell/well ratio for 40 plates using
standard SB method with PBMC from random donor
(5.times.10.sup.4/well); OKT3 (30 ng/ml); and IL-2 (100 CU/ml). On
days 29-31, the daughter cell clones were assayed against
allogeneic and ovarian cancer targets, where 54% of 150 clones were
allo-reactive and 67% of 34 clones were folate binding protein
(FBP)-reactive. Therefore, 36% of the clones were shown to be
reactive with both allogeneic PBMC and IGROV. On day 32, ten dual
specificity clones were expanded using random allogeneic PBMC and
the SB Rapid Expansion Protocol (REP). On days 43-44, the clones
were retested. The ten most reactive MOv-.gamma. transduced T cells
(410) were tested and found to be both allo- and IGROV-reactive as
measured by GM-CSF release (pg/ml). The results of FIG. 9 show that
non-transduced T cells are allogeneic-reactive, whereas, bulk
MOV-.gamma. transduced 410 T cells are both allogeneic- and
IGROV-reactive as measured by GM-CSF release (pg/ml). FIGS. 10A-10B
and Table 3 describe the phenotypic characteristic of the bulk
population of patient 410 anti-556 donor cells. The majority of
cells are CD4 helper T cells and were found to be reactive against
IGROV. Therefore, dual specificity human T cells can be grown to
recognize both allogeneic targets as well as tumor. Table 4 shows
GM-CSF secretion from ten of the most reactive transduced dual
specificity PBMC 410 clones. These results confirm that each clone
is both alloreactive as demonstrated by the high GM-CSF release in
response to PBMC 556 donor and specific for ovarian cancer as
demonstrated by the high GM-CSF secretion in response to IGROV.
FIGS. 11A-11J show the phenotype characterizations of
representative selected clones 1, 3, 5, 8, and 9. Although there is
some variation in whether the clone is CD4+, CD8+, or both
CD4+/CD8+, all clones recognize the presence of the ovarian cancer
specific receptor on T cells.
TABLE-US-00003 TABLE 3 Quad Events % Gated % Total CD4+/CD8- 6237
82.27 43.42 CD4+/CD8+ 233 3.07 1.62 CD4-/CD8- 116 1.53 0.81
CD4-/CD8+ 995 13.12 6.93
TABLE-US-00004 TABLE 4 CLONE 1 2 3 4 5 6 7 8 9 10 PBMC410 1010 650
1790 640 1580 2380 2330 70 250 0 PBMC556 2300 2410 >5000 3200
>5000 4870 >5000 3050 1330 1020 888 105 0 20 0 750 130 100 0
0 10 mel IGROV 2820 2690 2770 2200 3440 4850 2380 2290 5270
2400
Example 9
Optimization for Generating the Highest Number of Dual Reactive T
Cells
[0083] In order to maximize proliferation and reactivity against
both allogeneic and tumor targets which can be utilized for patient
treatment, the type of stimulator cells, the stimulator:responder
ratio in MLR, IL-2 concentration, and conditions for restimulation
must be optimized. Therefore, 2.times.10.sup.6 fresh responder PBMC
from a normal donor were incubated in wells of a 24 well plate with
a stimulator comprising one of irradiated allogeneic PBMC, B cells,
or DC at the following stimulator to responder ratios: 5:1, 1.5:1,
1:2, 1:6, 1:20, and 1:60 in AIM-V/5% human serum; 100 CU IL-2/ml).
After 3 days incubation, the cells were transduced with
MOv-.gamma./TCR by replacing of the media with retroviral
supernatant followed by centrifugation at 2700 rpm for 1 hour.
Transduction was repeated the following day, and cells were then
selected in 0.5 mg/ml G418. FIGS. 12A-12D show growth curves
following stimulation with various allogeneic cell types and at
various stimulator:responder ratios. FIG. 12D is the control
responder without stimulators. Table 5 describes the phenotype of T
cell cultures generated from a variety of APC and stimulator to
responder ratios on day 17.
[0084] Tables 6-9 show the results of functional assays of cells on
day 17 after stimulation for the various APC and stimulator:
responder ratios, where the different ratios were performed in
duplicates. Allogeneic PBMC were determined to be good stimulators
for MLR, and result in high levels of expansion when using
stimulator:responder ratios ranging from 1.5:1 to 5:1. Functional
assays demonstrated that transduced cells generated from PBMC
stimulators were capable of recognizing allogeneic and tumor
targets.
TABLE-US-00005 TABLE 5 Phenotype CD4+/ APC Stim:Resp CD3+ CD4+ CD8+
CD4+/CD8+ CD8- PBMC 1:60 93 4 51 2 43 1:20 94 4 49 2 45 1:6 1:2 88
9 43 4 45 1.5:11 91 15 41 5 40 5:1 95 19 42 7 32 DC 1:60 96 9 54 5
33 1:20 99 25 44 10 21 1:6 100 64 11 20 5 1:2 ND ND ND ND ND 1.5:1
ND ND ND ND ND 5:1 ND ND ND ND ND B-cells 1:60 90 10 41 4 45 1:20
86 18 34 6 42 1:6 88 25 28 8 40 1:2 96 54 16 12 18 1.5:1 98 67 12
15 7 5:1 99 76 10 11 3 OKT3 -- 99 56 27 16 2 No -- 93 5 52 3 40
OKT3 (ND = Not done) (CD4/CD8 double negative cells were CD3+,
CD19-, CD14-, CD11c-)
TABLE-US-00006 TABLE 6 PBMC (IFN gamma pg/ml) Stim:resp 1:60 1:20
1:6 1:2 1.5:1 5:1 media 59 48 37 31 33 38 27 24 44 34 50 49 alone
IGROV-1 2785 2200 3122 2973 3320 2815 2319 2349 3251 3755 4733 4279
888 185 614 165 172 65 66 38 42 65 69 100 91 stim. 107 97 174 261
443 631 548 612 1553 1693 1802 1244 PBMC responder 245 156 212 176
131 136 313 118 141 148 269 172 PBMC coated 7018 7155 5916 6172
4950 6083 3627 3765 5078 5019 >11060 7391 OKT3
TABLE-US-00007 TABLE 7 DC (IFN gamma pg/ml) Stim:resp 1:60 1:20 1:6
media alone 28 34 27 27 28 60 IGROV-1 2636 3102 3785 4131 1583 889
888 79 74 471 422 51 62 stim. PBMC 995 1054 1683 1463 1553 1921
responder 350 121 76 85 104 57 PBMC coated OKT3 5965 7019 9385 9727
6211 5108
TABLE-US-00008 TABLE 8 B Cells (IFN gamma pg/ml) Stim:resp 1:60
1:20 1:6 1:2 1.5:1 5:1 media 30 35 30 41 81 62 39 28 10 10 7 2
alone IGROV-1 1374 1543 2894 3270 4634 3548 3686 3181 1583 1463 350
341 888 124 122 79 63 100 95 47 45 11 11 2 3 stim. 680 1090 1433
1314 1081 895 761 518 308 228 96 123 PBMC responder 139 114 399 161
349 133 83 79 50 44 31 33 PBMC coated 7096 4999 5640 4871 6240 7303
6014 5916 5384 5728 886 994 OKT3
TABLE-US-00009 TABLE 9 Stimulators (IFN gamma) +OKT3 No OKT3 media
alone 2 0 23 23 IGROV-1 1832 2259 2646 2587 888 16 18 50 84 stim.
PBMC 16 17 43 72 responder 90 50 189 131 PBMC coated OKT3 3656 3815
6585 5561
[0085] Following the first stimulation, 4.times.10.sup.5 of the T
cells from each group were added to the appropriate number and type
of stimulator cells (from the same allogeneic donor) in a 24 well
plate with 50 CU IL-2/ml and 5% AIM-V human serum. IL-2 (50 CU/ml)
was added every 2 days. FIGS. 13A-13D show the number of transduced
cells upon further stimulation.
Example 10
Optimization of IL-2 Concentrations for Maximized Cell Number and
Reactivity Against Allogeneic and Tumor Targets
[0086] Human alloreactive T cells from cryopreserved cells were
generated using PBMC at a ratio of 1:1 (2.times.10.sup.6 stimulator
to 2.times.10.sup.6 responder/well), in the presence of various
IL-2 concentrations. T cells were transduced with MOv-.gamma. and
selected in 0.5 mg/ml G418 for 5 days. Proliferation and reactivity
against allogeneic and tumor targets were determined. FIG. 14 shows
T cell growth in MLR with various IL-2 concentrations in CU/ml.
Results indicate that as the concentration of IL-2 increases, the
number of T cells generated also increases. The phenotypic
characteristics of T cell cultures generated from a variety of IL-2
concentrations is depicted in Table 10. At all concentrations of
IL-2, T cells are predominantly CD3-1- and then CD4+. In Table 11,
the function of MOv-.gamma. transduced alloreactive T cells grown
in a variety of IL-2 concentrations as measured by IFN-.gamma.
release (pg/ml) demonstrates that 50 CU IL-2/ml provides good
expansion, as well as a high level of reactivity against both
allogeneic and tumor targets.
TABLE-US-00010 TABLE 10 [IL-2] Phenotype (CU/ml) CD3+ CD4+ CD8+
CD4+/CD8+ CD4+/CD8- 12.5 80 50 23 4 22 25 83 58 22 7 14 50 71 49 22
2 27 100 70 38 28 6 28
TABLE-US-00011 TABLE 11 Stimulator (IFN gamma pg/ml) media
Responder Stimulator alone 888 mel IGROV-1 PBMC PBMC media alone 0
0 0 0 0 0 0 0 0 0 12.5 CU/ml IL-2 4 0 353 318 879 725 278 263 3900
3850 25 CU/ml IL-2 4 4 118 138 2280 2140 239 210 2420 3450 50 CU/ml
IL-2 2 12 68 77 2460 2210 235 248 4880 4830 100 CU/ml IL-2 8 8 746
688 2900 2900 231 247 1850 2830
Example 11
Generation of Human Peripheral Blood Lymphocytes Transduced with
the Mov-.gamma. Chimeric Receptor Gene
[0087] Serum-free AIM-V medium is supplemented with penicillin G
(50 units/ml), and L-glutamine (292-584 mg/ml, 2 mM), as well as
IL-2 (100 CU/ml). If necessary, AIM-V medium can also be
supplemented with 1-10% human serum (type AB heat inactivated at
56.degree. C. for 30 minutes).
[0088] PBL is isolated by leukapheresis. Lymphocytes are separated
by centrifugation 1000 g (2700 rpm) on a Ficoll cushion. PBL is
subjected to multiple exposures of retroviral supernatant, for up
to 3 days. The PBL is then selected for 5 days in 0.5 mg/ml of the
neomycin analog G418 (Geneticin; Gibco; Grand Island, N.Y.).
Following G418 selection, PBL is expanded in AIM V media with 100
CU/ml IL-2. If necessary, AIM V is supplemented with 1-10% human AB
serum. The exact days stated below is an approximation of what is
expected for PBL transduction.
[0089] On Day 0, isolate PBMC from the leukapheresis preparation
from patient and donor by Ficoll-Hypaque gradient centrifugation.
Wash in Ca.sup.2+-, Mg.sup.2+-, Phenol red free Hanks' balanced
salt solution (HBSS; BioWhittaker), then resuspend in AIM V medium
supplemented with 50 CU/ml of IL-2. Irradiate donor PBMC with 5000
rads. Co-culture irradiated donor PBMC with patient PBMC at a ratio
of 2:1 to 5:1.
[0090] On Day 3, harvest PBMC and resuspend in retroviral
supernatant supplemented with 50 CU/ml of IL-2 and 8 .mu.g/ml
polybrene. Replate PBMC at a concentration of 1.times.10.sup.6 per
ml; 2 ml per well in 24 well plates. Centrifuge plates at 1000 g
(2700 rpm in Sorvall tabletop centrifuge) for 1 hour.
[0091] On Day 4, remove 1 ml of media per well and replace with 1
ml of freshly thawed retroviral supernatant supplemented with 50
CU/ml of IL-2 and 8 .mu.g/ml polybrene. Centrifuge plates at 1000 g
(2700 rpm in Sorvall tabletop centrifuge) for 1 hour.
[0092] On Day 5, remove two-thirds of media per well and replace
with AIM V medium supplemented with 50 CU/ml of IL-2.
[0093] On Day 6, harvest the PBL, and resuspend at 1.times.10.sup.6
per ml in AIM V medium supplemented with 50 CU/ml of IL-2 and 0.5
mg/ml G418. Replate cells in appropriate size Fenwal bag (Baxter)
or T-175 tissue culture flask. Aliquot 5.times.10.sup.6 cells from
non-transduced (NV) and transduced PBL groups for PCR analysis.
[0094] Every 2-3 days, count cells and dilute to 1.times.10.sup.6
cells per ml in AIM V medium supplemented with 50 CU/ml of IL-2 and
0.5 mg/ml G418.
[0095] On day 11, harvest the PBL, and resuspend at
1.5.times.10.sup.6 per ml in AIM V medium supplemented with 50
CU/ml of IL-2. Replate cells in appropriate size Fenwal bag or
T-175 tissue culture flask.
[0096] Between Days 14-21, the PSL are screened for specific
cytokine release against the ovarian tumor cell line IGROV-1, and
phenotype by FACS analysis. Aliquot 5.times.10.sup.6 transduced,
selected PBL for PCR analysis. Send samples for S+L-assay for
retrovirus.
[0097] On approximately day 21, the patient PBMC are restimulated
with irradiated donor PBMC at a ratio of 1:1 to 2:1
(donor:patient).
[0098] The density of PBL is maintained between 1.times.10.sup.6
and 2.5.times.10.sup.6 PBL/ml. Once PBL have begun to grow, the
cultures are assessed for growth every 3-4 days to insure that they
do not increase beyond 2.5.times.10.sup.6/ml.
[0099] Once the total PBL count reaches about 5.times.10.sup.8, PBL
are removed from the tissue culture plates or flasks and cultured
further in Fenwal PL732 cell culture bags. These bags have a
1-liter capacity, but normally 500 mls medium are the maximum used
in each bag. PL732 bags are gas permeable, but impermeable to
fluids. Thus, oxygen and CO.sub.2 are freely exchanged while tissue
culture medium and cells are maintained inside. Using an inverted
syringe (plunger removed), suspended by a clamp on a ring stand,
connect the needle-adapter end of the syringe to the female-luer
port of the 1 liter PL732 bag. Pour the cells from the 250 ml
conical centrifuge tube into the bag through the syringe, and to
obtain a cell concentration of 1.times.10.sup.6 PBL/ml add the
appropriate volume of fresh AIM-V (serum-free medium) containing
the following added supplements (final concentrations): 50 units/ml
penicillin G sodium (BioWhittaker), 146 g/ml L-glutamine (Media
Tech), 1.25 mg/ml Fungizone, and IL-2 (50 CU/ml).
[0100] As the PBL continue to grow, they are transferred to a 3
liter capacity PL732 bag (1500 ml/bag, 1.5.times.10.sup.9 PBL/bag)
via the male- and female-luer sterile tubing ports of both the 1
liter and 3 liter bags. The appropriate volume of AIM V medium is
then added to maintain the PBL at 1.times.10.sup.6/ml. Medium is
added to the 3 liter bag using the same sterile tubing attached to
an inverted syringe, as described above. PL732 bags are
advantageous in that access to the medium containing cells is
limited to injection sites and sterile tubing ports, both of which
can be maintained aseptically.
[0101] After the PBL are transferred to PL732 bags, PBL cell counts
are done every 3-4 days. When the PBL density reaches
2.0.times.10.sup.6/ml or greater, the PL732 bags containing medium
and PBL are "split" 1:2 or 1:3 to reduce the PBL concentration to a
level of 1.times.10.sup.6/ml or a bit above. For example, a 1:2
split of cells at 2.0.times.10.sup.6/ml involves transferring 500
mls of medium (containing PBL) to a new 3 liter PL732 bag and
adding 500 mls of AIM-V containing IL-2 to bring the total volume
up to 1000 ml. The AIM-V being added to the 3 liter PL732 bag is
transferred from a 10 liter STAK PACK of AIM-V medium (GIBCO; Life
Technologies, Grand Island, N.Y.) using a sterile Solution transfer
set, Life-adapter set, 8'' Interconnecting jumper tube, and a Fluid
fill/weigh unit.
[0102] When PBL have been expanded beyond 3 bags (about 1500 mls
each), at least 4.times.10.sup.9 cells
(generally)1.times.10.sup.1.degree. may be removed for bulk
freezing in a bag, keeping at least 4.times.10.sup.9 PBL in culture
in order to generate cells for treating the patient. For a rapidly
growing culture, the PBL might be removed a week before treatment.
However, for slower growing PBL might not be removed for freezing
until the day of harvest. PBL are commonly used for treatment after
14-45 days in culture.
[0103] In general, PBL doubling time is 1.5 to 3 days. Thus, PBL
cultures are generally split to new bags containing fresh medium
every 3-5 days. Fungizone is left out of the last passage of cells
in bags to minimize adverse effects on the patients. Of note, a
sample is collected from the last passage of PBL for microbiology
tests; this should be done 2-5 days prior to the beginning of PBL
therapy. The test takes 2 days. The bags are then harvested for
treatment using an automated process of cell harvesting as
described by Muul, et al. J. Immunol. Methods 101:171, 1987).
[0104] Following the last split of cells prior to use for
treatment, tests are done for bacterial and fungal contamination
from samples representing 10% of the bags. If treatment occurs
earlier than expected, such that Fungizone is present in the PBL
growth medium, PBL harvested for treatment should be washed with 9
liters of isotonic saline, rather than the usual 3 liters. Cells
can be infused with up to 75,000 CU IL-2 per infusion bag.
[0105] PBL are infused in a volume of 200-300 ml of saline
supplemented with 50 ml of 25% human albumin (Alpha Therapeutic
Co.). Cells are infused over 30-60 minutes through a central venous
catheter. Patients receiving dual specificity cells are immunized
with donor PBMC 1 and 8 days after each cell infusion. Each
immunization is performed with up to 5.times.10.sup.9 donor PBMC,
depending on the number of cells available, administered
subcutaneously in the thighs at a concentration of up to
7.times.10.sup.8 PBMC per ml of injectate.
[0106] Cryopreserved, transduced PBL can be thawed for subsequent
cycles or courses of therapy. If necessary, repeat transduction may
be performed on either fresh PBL or cryopreserved, non-transduced
PBL.
[0107] IL-2 is administered at a dose of 120,000 CU/kg as an
intravenous bolus over a 15 minute period every twelve hours
beginning on the day of PBL administration and continuing for up to
eight doses. Doses may be skipped depending on patient tolerance.
Also, if patients reach Grade III or IV toxicity (not easily
reversed) due to IL-2 except for the reversible Grade III
toxicities common to IL-2 such as diarrhea, nausea, vomiting,
hypotension, skin changes, anorexia, mucositis, dysphagia, or
constitutional symptoms and laboratory changes as detailed in Table
12, doses are not administered. If this toxicity is easily reversed
by supportive measures then additional doses are given. No more
than 12 doses of IL-2 is ever administered.
TABLE-US-00012 TABLE 12 Toxicity of Treatment with IL-2 Total
Number of patients 652 Number of courses 1039 Chills 399 Pruritus
180 Necrosis 5 Anaphylaxis 1 Mucositis (requiring liquid diet) 30
Alimentation not possible 4 Nausea and vomiting 666 Diarrhea 596
Hyperbilirubinemia (maximum/mg %) 2.1.-6.0 547 6.1-10.0 179 10.1+
83 Oliguria <80 ml/8 hours 347 <240 ml/24 hours 42 Weight
gain (% body weight) 0.0-5.0 377 5.1-10.0 436 10.1-15.0 175
15.1-20.0 38 20.1+ 13 Elevated creatinine (maximum/mg %) 2.1-6.0
637 6.1-10.0 85 10.1.sub.-- 10 Hematuria (gross) 2 Edema
(symptomatic nerve or vessel compression) 17 Tissue ischemia 2
Resp. distress: not intubated 67 intubated 41 Bronchospasm 9
Pleural effusion (requiring thoracentesis) 17 Somnolence 114 Coma
33 Disorientation 215 Hypotension (requiring pressors) 508 Angina
22 Myocardial infarction 6 Arrhythmias 78 Anemia requiring
transfusion (number units transfused) 1-15 377 6-10 95 11-15 24 16+
14 Thrombocytopenia (minimum/mm.sup.3) <20,000 131 20,001-60,000
361 60,001-100,00 285 Central line sepsis 63 Death 10
[0108] IL-2 (Chiron), NSC #373364, is provided as a 5 mL vial
containing 1.3 mg of protein as a lyophilized powder cake, with
mannitol 50 mg and Sodium Dodecyl Sulfate 130 .mu.g per milligram
of protein. The 1.3 mg of protein is equivalent to approximately
21.6 million International Units (IU) or 3.6 million Cetus units
(CU), where 600 IU=100 CU. The vial is reconstituted with 2.0 mL of
Sterile Water for Injection, USP, and the resultant concentration
is 10.8 million IU/ml or 1.8 million CU/ml. Diluent should be
directed against the side of the vial to avoid excess foaming.
Contents are gently swirled, not shaken, until completely
dissolved. Since vials contain no preservative, reconstituted
solution should be used with 8 hours.
[0109] Intact vials are stored in the refrigerator (2-8.degree. C.)
protected from light. Each vial bears an expiration date.
[0110] Reconstituted IL-2 is further diluted with 50 mL of 5% Human
Serum Albumin (HSA). The HSA is added to the diluent prior to the
addition of recombinant IL-2. Dilutions of the reconstituted
solution over a 1000-fold range (i.e., 1 mg/mL to 1 .mu.g/mL) are
acceptable in either glass bottles or polyvinyl chloride bags.
Reconstituted solutions are not mixed with saline-containing
solutions. IL-2 is chemically stable for 48 hours at refrigerated
and room temperatures, 2-30.degree. C.
[0111] All patients receiving IL-2 also receive concomitant
medications to relieve side effects as in all previous high-dose
IL-2 protocols. The following concomitant medication begins the
evening before the first dose of IL-2 and continues throughout the
entire cycle of treatment: acetaminophen (650 mg every 4 hr),
indomethacin (50-75 mg every 6-8 hr), and ranitidine (150 mg every
12 hr). Patients receive intravenous meperidine (25 to 50 mg) to
control chills when they occur, although chills are unusual after
the first one to two doses of IL-2. Ondansetron, droperidol, or
scopolamine is available as needed for the treatment of nausea
during treatment. Steroids are not used in these patients and if
steroids are required then the patient should be taken off protocol
therapy.
Example 12
"REP" Expansion of CTL Clones to Therapeutic Numbers
[0112] If PBL fail to expand to adequate numbers, then cultures may
be expanded using 1000 CU/ml IL-2 or the "Rapid Expansion Protocol"
(REP) as described below: MOv-transduced PBL are counted and the
specified number is used (Table 13). In the REP cycle immediately
preceding infusion, 1.25 mg/ml Fungizone and 1 ml/L Cipro are added
on day 8, and AIM V media is used.
[0113] On day 0 PBMC are thawed, washed twice in AIM V media,
resuspended in complete media (CM; RPMI media) and irradiated (340
Gy) as described above. PBMC and OKT3 are added to CM, mixed well,
and aliquots are transferred to tissue culture flasks. Viable cells
are added last. Flasks are incubated upright at 37.degree. C. in 5%
CO.sub.2.
On day 2 IL-2 is added to a final concentration of 50 CU/ml.
[0114] On day 5 20 ml (130 ml for a 175 cm.sup.2 flask) of culture
supernatant is removed by aspiration (cells are retained on the
bottom of the flask). Media is replaced with CM containing 50 CU/ml
IL-2.
[0115] On day 8, an aliquot of cells is removed for counting and is
further analyzed (ELISA, FACS, etc.). If cell density is greater
than 1.times.10.sup.6/ml, cells are split into additional flasks or
transferred to Baxter 3 liter culture bags. IL-2 is added to 50
CU/ml. Fungizone is added to a final concentration of 1.25 mg/ml
and 1 ml/L Cipro is added.
[0116] On day 11, IL-2 is added to a final concentration of 50
CU/ml. Cells are split if density exceeds 1.5.times.10.sup.6
cells/ml.
[0117] On day 14, cells are harvested and either prepared for
additional REP cycles or cryopreserved. In general, REP expansion
of CTL clones results in 50-200 fold expansion. Thus, 2-3 REP
cycles could be required to generate a sufficient number of cells
for patient treatment. If cells have grown to sufficient numbers
for patient treatment, a sample is collected from each flask for
microbiology tests 2-3 days before the beginning of PBL therapy
(the test takes 2 days). IL-2 is added to a final concentration of
50 CU/ml on day 14 and every 3 days until the final product is
prepared for infusion.
TABLE-US-00013 TABLE 13 Component 25 cm.sup.2 flask 150 cm.sup.2
flask viable transduced PBL 1 .times. 10.sup.5 1 .times. 10.sup.6
allogeneic PBMC 2.5 .times. 10.sup.7 2 .times. 10.sup.8 OKT3 30
ng/ml 30 ng/ml CM 25 ml 75 ml AIM V 75 ml
Example 13
Assessment of Patient Response to Therapy
[0118] A complete response is defined as the disappearance of all
clinical evidence of disease that lasts at least four weeks.
Partial response is defined as a 50% or greater decrease in the sum
of the products of the maximal perpendicular diameter of all
measurable lesions for at least four weeks with no appearance of
new lesions or increase in any lesions. A minor response is defined
as a 25-49% decrease in the sum of the products of the maximal
perpendicular diameters of all measurable lesions but no appearance
of new lesions and no increase in any lesion.
[0119] Any patient with less than a minor response will be
considered a nonresponder. The appearance of a new lesion or a
greater than 25% increase in the product of perpendicular diameters
of any prior lesion following a partial or complete response will
be considered a relapse.
Example 14
Generation of Recombinant Viral Vector Encoding the MOv-.gamma.
Chimeric Receptor
[0120] Retroviral supernatant containing the MOv-.gamma. chimeric
receptor gene was used for lymphocyte transductions (Retroviral
supernatant to be produced by Somatix, Inc, Alameda Calif.).
[0121] For the generation of high-titer recombinant viral vector
encoding the MOv-.gamma. chimeric receptor, the MFG-S retroviral
vector and the .psi.-CRIP packaging cell line were used (Danos, O.
and R. C. Mulligan. Proc. Natl. Acad. Sci. U.S.A., 85:6460-6464,
1988), similar to that approved for use in ongoing clinical trials
(Jaffee, et al. Cancer Res., 53:2221-2226, 1993). In the MFG-S
vector, Moloney murine leukemia virus (MoMLV) long terminal repeat
(LTR) sequences were used to generate both a full length viral RNA
necessary for the generation of viral particles and a subgenomic
mRNA analogous to the MO-MuLV envelope RNA, which is responsible
for the expression of the MOv-.gamma. gene (FIG. 15). The vector
retained sequences in both the viral gag region shown to improve
the encapsidation of viral RNA and the normal viral 5' and 3'
splice sites necessary for generation of the subgenomic RNA. Three
additional point mutations were introduced into the viral gag
region to eliminate the potential expression of two overlapping
open reading frames (ORFs), which encode the NH.sub.2 portion of
both the cell surface and cytoplasmic gag-pol polyproteins. DNA
sequences encoding MOv-.gamma. were inserted such that the
initiation codon of the inserted sequences was placed precisely at
the position normally occupied by the initiation codon for env
translation, and minimal 3' non-translated sequences were included
in the insert. The entire DNA sequence from LTR to LTR was
determined for both strands of the vector and no mutations or base
substitutions were discovered.
[0122] The T-CRIP cell line provided the viral proteins necessary
for encapsidation of recombinant retroviral genomes into infectious
particles. As is the case with other packaging cell lines, the
expression of the relevant viral gene products in .PSI.-CRIP cells
is accomplished in a manner designed to prevent the encapsidation
and mobilization of the RNA molecules encoding the viral gene
products. This makes possible the generation of stocks of
replication-deficient recombinant virus, free of
replication-competent virus.
[0123] High titer stocks of recombinant virus suitable for clinical
use were generated from cultures derived from the working cell bank
(WBC) propagated in a closed-loop perfusion system designed for the
mass culture of anchorage dependent cells. The system allowed the
culture medium to be monitored for perfusion rate, oxygen levels,
and pH, permitting the growth and maintenance of large numbers of
cells in a minimal volume of medium. In its current configuration,
approximately 5.times.10.sup.10 cells were cultured in a single
vessel which minimized the risk of contamination from handling
multiple flasks, and additionally ensured a consistent lot of
recombinant virus.
[0124] To initiate a production run, a vial of the WCB of the
producing cell line was thawed and expanded in culture to generate
sufficient numbers of cells to seed the bioreactor. During this
brief scale-up period, the cells were re-tested for sterility and
mycoplasma contamination. The system was then seeded and monitored
until the optimal cell density is achieved. At this point, fresh
culture supernatant was collected, filtered, and stored in frozen
aliquots for quality control and safety testing as required for FDA
approval, followed by clinical use.
[0125] The foregoing description of the specific embodiments will
so fully reveal the general nature of the invention that others
can, by applying knowledge within the skill of the art (including
the contents of the references cited herein), readily modify and/or
adapt for various applications such specific embodiments, without
undue experimentation, without departing from the general concept
of the present invention. Therefore, such adaptations and
modifications are intended to be within the meaning and range of
equivalents of the disclosed embodiments, based on the teaching and
guidance presented herein. It is to be understood that the
phraseology or terminology herein is for the purpose of description
and not of limitation, such that the terminology or phraseology of
the present specification is to be interpreted by the skilled
artisan in light of the teachings and guidance presented herein, in
combination with the knowledge of one of ordinary skill in the art.
Sequence CWU 1
1
419PRTArtificial SequenceSynthetic 1Thr Thr Ala Glu Glu Ala Ala Gly
Ile1 529PRTArtificial SequenceSynthetic 2Ala Ala Gly Ile Gly Ile
Leu Thr Val1 5310PRTArtificial SequenceSynthetic 3Glu Ala Ala Gly
Ile Gly Ile Leu Thr Val1 5 10410PRTArtificial SequenceSynthetic
4Ala Ala Gly Ile Gly Ile Leu Thr Val Ile1 5 10
* * * * *